Periodic Report of the United States of America to the United Nations Committee Against Torture

Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody

Retrieved on: 
Monday, November 21, 2022
Immunosuppression, VISTA, IND, Risk, CD39, Knowledge, Safety, Patient, Society, Immunotherapy, Society for Immunotherapy of Cancer, Tumor microenvironment, Annual report, Research, Annual general meeting, Washington University in St. Louis, Senior, Neoplasm, Pathology, Cancer, SITC, Therapy, Investigational New Drug, Immunology, FDA, Periodic Report of the United States of America to the United Nations Committee Against Torture, Northwest Biotherapeutics, Pharmaceutical industry, Medical imaging, Sensei

Said Dr. Schreiber, Were excited to partner with Sensei Bio to further our understanding of how to safely and effectively inhibit VISTA, a promising but challenging target in immuno-oncology.

Key Points: 
  • Said Dr. Schreiber, Were excited to partner with Sensei Bio to further our understanding of how to safely and effectively inhibit VISTA, a promising but challenging target in immuno-oncology.
  • Sensei continues to advance SNS-101 and remains on track to submit an Investigational New Drug application (IND) for SNS-101 in the first half of 2023.
  • Dr. Schreiber receives compensation as a member of Sensei Biotherapeutics Immuno-Oncology Advisory Board, and this financial relationship has been disclosed to Washington University in St. Louis in accordance with institutional policy.
  • Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022
Molecule, Bausch & Lomb, Choroid, GLOBE, Private Securities Litigation Reform Act, Investor, Periodic Report of the United States of America to the United Nations Committee Against Torture, SCS, Pharming, Annual general meeting, Safety, Webcast, American Academy of Ophthalmology, Society, Eye, ASRS, CLS, SEC, Annual report, NASDAQ, American Academy, OIS, AMD, U.S. Securities and Exchange Commission, Axitinib, Retina, Company, Government, Research, Conference, Awareness, Patient, ET, AAO, OASIS, COVID-19, Conference call, Pharmaceutical industry, Medical device, Video game, Clearside

ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Clearsides license and other revenue for the third quarter of 2022 was $0.3 million, compared to $3.1 million for the third quarter of 2021.
  • Research and development expenses for the third quarter of 2022 were $4.6 million, compared to $5.1 million for the third quarter of 2021.
  • General and administrative expenses for the third quarter of 2022 were $2.4 million, compared to $2.8 million for the third quarter of 2021.

Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
LinkedIn, U.S. Securities and Exchange Commission, CD8, Therapy, Risk, SEC, Northwest Biotherapeutics, SITC, Annual report, NASDAQ, Neoplasm, Periodic Report of the United States of America to the United Nations Committee Against Torture, Twitter, Annual general meeting, Immunotherapy, Nasdaq, VISTA, Cancer, Private Securities Litigation Reform Act, Tumor microenvironment, Society, Safety, Phrase, GLOBE, Society for Immunotherapy of Cancer, Pharmaceutical industry, Vaccine, Sensei

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA from November 8 - 12, 2022.

Key Points: 
  • BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA from November 8 - 12, 2022.
  • The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications.
  • These forward-looking statements include expectations regarding the development of Senseis product candidates and platforms; the potential safety profile of Senseis product candidates; and the potential benefits of Senseis product candidates.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Retrieved on: 
Friday, September 30, 2022
Cytokine release syndrome, Therapy, Safety, Syngenic, Twitter, Risk, Neoplasm, U.S. Securities and Exchange Commission, VISTA, Washington University in St. Louis, LinkedIn, Northwest Biotherapeutics, Senior, George Washington University School of Engineering and Applied Science, Private Securities Litigation Reform Act, Periodic Report of the United States of America to the United Nations Committee Against Torture, Phrase, Cancer, Annual report, Nasdaq, CRS, NASDAQ, Pathology, Tumor microenvironment, Conference, Pharmacokinetics, GLOBE, Washington University School of Medicine, SEC, PD-1, The Year's Best Science Fiction: Twenty-Sixth Annual Collection, Translation, Vaccine, Science, Sensei, Survival

BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today presented additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The presentation contains data from an ongoing collaboration with scientists at Washington University, St. Louis, investigating the mechanism of action of SNS-101.

Key Points: 
  • The presentation contains data from an ongoing collaboration with scientists at Washington University, St. Louis, investigating the mechanism of action of SNS-101.
  • SNS-101 potently inhibited the critical pH-dependent interaction between VISTA and PSGL-1, as well as interactions with other putative receptors.
  • Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Connexa Sports Technologies Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Retrieved on: 
Monday, September 26, 2022
Securities Exchange Act of 1934, Mission statement, Digital, Securities Act of 1933, Company, Gameface, Compliance, Calendar, Periodic Report of the United States of America to the United Nations Committee Against Torture, File, Letter, Form 10-K, Tennis, PlaySight Interactive, Sport, NASDAQ, Form, GLOBE, First, Online gambling, Nasdaq

As previously disclosed, the Company received a letter from Nasdaq on August 16, 2022 (the First Letter) regarding the Company not filing its 2022 10-K.

Key Points: 
  • As previously disclosed, the Company received a letter from Nasdaq on August 16, 2022 (the First Letter) regarding the Company not filing its 2022 10-K.
  • The Notice Letter has no immediate effect on the listing or trading of the Company's shares.
  • This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
  • Connexa Sports a leading connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports.

Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Retrieved on: 
Wednesday, September 21, 2022
Therapy, Safety, AACR, Tumor microenvironment, Twitter, Risk, Research, Neoplasm, U.S. Securities and Exchange Commission, VISTA, New York Hilton Midtown, LinkedIn, Northwest Biotherapeutics, Date and time notation in the Netherlands, Poster, Private Securities Litigation Reform Act, Periodic Report of the United States of America to the United Nations Committee Against Torture, Phrase, Cancer, Annual report, Nasdaq, NASDAQ, Date, Conference, GLOBE, SEC, The Year's Best Science Fiction: Twenty-Sixth Annual Collection, Translation, Time, Vaccine, Science, Sensei, Survival

The full abstract will be available online as a supplement to the AACR journal, Cancer Immunology Research.

Key Points: 
  • The full abstract will be available online as a supplement to the AACR journal, Cancer Immunology Research.
  • The poster will be made available on the Sensei Bio website following the presentation.
  • Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

LMP Automotive Holdings, Inc. Provides a Corporate Update and Announces Delay of its Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 16, 2022
Periodic Report of the United States of America to the United Nations Committee Against Torture, Industry, GLOBE, Technology, LLC, Annual report, Calendar, Company, Acquisition, Transport, LMP, NASDAQ, Maintenance, Solution, Financial services, Video game

FORT LAUDERDALE, FL, Aug. 16, 2022 (GLOBE NEWSWIRE) -- LMP Automotive Holdings, Inc. (NASDAQ: LMPX) (LMP or the Company), an e-commerce and facilities-based automotive retailer in the United States, today provided a corporate update and announced a delay of its second quarter 2022 financial results for the period ended June 30, 2022.

Key Points: 
  • FORT LAUDERDALE, FL, Aug. 16, 2022 (GLOBE NEWSWIRE) -- LMP Automotive Holdings, Inc. (NASDAQ: LMPX) (LMP or the Company), an e-commerce and facilities-based automotive retailer in the United States, today provided a corporate update and announced a delay of its second quarter 2022 financial results for the period ended June 30, 2022.
  • During the first ten months of 2021, the Company acquired a majority interest in 15 new vehicle franchises, comprising 8 new dealership locations.
  • The Company also acquired a majority interest in LTO Holdings, LLC, a Connecticut based automotive leasing company with an associated collision center that was subsequently disposed during the fourth quarter.
  • LMP Automotive Holdings, Inc. (NASDAQ: LMPX) is a growth company with a long-term plan to profitably consolidate and partner with automotive dealership groups in the United States.

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Retrieved on: 
Monday, August 8, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diabetic retinopathy, U.S. Securities and Exchange Commission, ASEAN countries in sporting events, GLOBE, Form, Private Securities Litigation Reform Act, Growth, SEC, Macular edema, LLC, Bausch & Lomb, SCS, Annual report, Patient, 8-K, COVID-19, Periodic Report of the United States of America to the United Nations Committee Against Torture, Eye, Axitinib, AMD, VEGF, TKI, Uveitis, Ophthalmology, Secretary General of the ASEAN, Nasdaq, Pharming, Retina, Squamous cell carcinoma, Food, Choroid, Pharmaceutical industry, Clearside

Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses.

Key Points: 
  • Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses.
  • The terms of the agreement also provide for an additional milestone payment of $20 million to Clearside upon attainment of a second pre-specified 2024 sales milestone for XIPERE.
  • The arrangement with HealthCare Royalty specifically excludes all Clearsides internal development programs, including CLS-AX, as well as any future in-licensed assets.
  • HEALTHCARE ROYALTY PARTNERS is a registered trademark of HealthCare Royalty Management, LLC in the U.S. and a trademark in other countries.

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Retrieved on: 
Tuesday, July 26, 2022
Time, Eye, GLOBE, Axitinib, Injection, Blood, Retina, Sclera, SCS, U.S. Securities and Exchange Commission, SEC, AMD, Diabetic retinopathy, Severe cognitive impairment, Compliance, Private Securities Litigation Reform Act, Periodic Report of the United States of America to the United Nations Committee Against Torture, Safety, COVID-19, TKI, Choroid, VEGF, MBA, Squamous cell carcinoma, Patient, Nasdaq, Pharmacokinetics, Suprachoroidal drug delivery, Annual report, Google Images, Growth, Pharmaceutical industry, Medical imaging, Clearside

ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today completion of dosing in Cohorts 3 and 4 of OASIS, its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).

Key Points: 
  • OASIS is a U.S.-based, multi-center, open-label, dose-escalation trial in wet AMD patients to assess the safety and tolerability of a single dose of CLS-AX administered by suprachoroidal injection.
  • There is also an ongoing extension study to follow patients in Cohorts 2, 3 and 4 for three months after their completion of OASIS.
  • We are grateful to all our investigators and patients whose time and commitment made this first-in-human, suprachoroidal tyrosine kinase inhibitor trial possible.
  • OASIS is an open-label, dose-escalation Phase 1/2a trial in wet AMD patients to assess the safety and tolerability of a single dose of CLS-AX administered by suprachoroidal injection via Clearsides SCS Microinjector.

LMP Automotive Holdings, Inc. Provides a Corporate Update and Announces Delay of its First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 18, 2022
Company, Periodic Report of the United States of America to the United Nations Committee Against Torture, NASDAQ, Solution, Transport, Industry, LMP, Technology, Calendar, Maintenance, Acquisition, LLC, Annual report, Online gambling, Video game

LMP Automotive Holdings, Inc. (NASDAQ: LMPX) (LMP or the Company), an e-commerce and facilities-based automotive retailer in the United States, today provided a corporate update and announced a delay of its first quarter 2022 financial results for the period ended March 31, 2022.

Key Points: 
  • LMP Automotive Holdings, Inc. (NASDAQ: LMPX) (LMP or the Company), an e-commerce and facilities-based automotive retailer in the United States, today provided a corporate update and announced a delay of its first quarter 2022 financial results for the period ended March 31, 2022.
  • During the first ten months of 2021, the Company acquired a majority interest in 15 new vehicle franchises, comprising 8 new dealership locations.
  • The Company will hold a conference call to discuss these financial results when it ascertains a definitive filing date.
  • LMP Automotive Holdings, Inc. (NASDAQ: LMPX) is a growth company with a long-term plan to profitably consolidate and partner with automotive dealership groups in the United States.